L’évolution des traitements de l’adénome prostatique au cours des 10 dernières années.

Endoscopy; Humans; Laser Therapy; Lasers, Solid-State; Male; Prostatic Hyperplasia/therapy; Treatment Outcome; BPH; HoLEP; Laser endoscopic enucleation of the prostate; Prostatic surgery; Benign prostatic hyperplasia

Abstract :

[en] Benign prostatic hyperplasia (BPH) is a very frequent condition, most of the times related to age, and with initial manifestations and long term development that may vary widely. Treatment is necessary only if the patient is symptomatic or if he has complications related to the BPH. During the last 10 years, the various BPH treatment means have evolved significantly. Regarding medical treatment, new drugs have been introduced and new combinations of drugs have shown their efficacy in BPH treatment. The surgical treatment of BPH has seen the development of minimally invasive surgical techniques, with broader indications and better results compared to classical surgical techniques. Among these techniques, the better studied and developed is the endoscopic Holmium Laser Enucleation of the Prostate (HoLEP). The continuous development of medical lasers and minimally invasive surgical techniques for the treatment of BPH will, in our opinion, lead the way towards a rich and innovative future decade with regard to the surgical treatment of BPH.

Research center :

Service d'Urologie

Disciplines :

Urology & nephrology

Author, co-author :

TRIFFAUX, François ; Centre Hospitalier Universitaire de Liège - CHU > Département de chirurgie > Service d'urologie

Waltregny, David ; Université de Liège - ULiège > Département des sciences cliniques > Urologie

Nechifor Vlad, Andrei ; Université de Liège - ULiège > Département des sciences cliniques > Département des sciences cliniques

Language :

French

Title :

L’évolution des traitements de l’adénome prostatique au cours des 10 dernières années.

Alternative titles :

[en] What the last 10 years have brought in the treatment of benign prostatic hyperplasia

Publication date :

2020

Journal title :

Revue Médicale de Liège

ISSN :

0370-629X

eISSN :

2566-1566

Publisher :

Université de Liège. Revue Médicale de Liège, Liège, Belgium

Volume :

Issue :

5-6

Pages :

440-444

Peer reviewed :

Peer reviewed

Commentary :

L’hyperplasie bénigne de la prostate (HBP) est une pathologie extrêmement fréquente, favorisée par le vieillissement et dont les manifestations cliniques peuvent être très variées. Un traitement n’est nécessaire que lorsque le patient se plaint de symptômes secondaires à l’HBP ou souffre de ses complications. Ces 10 dernières années, les traitements de l’adénome prostatique ont évo- lué de manière importante. De nouvelles molécules ainsi que de nouvelles associations (de molécules connues ayant déjà prouvé leur efficacité) se sont ajoutées au trai- tement médical. Le traitement chirurgical, quant à lui, a été significativement marqué par le développement des tech- niques mini-invasives, aux indications plus larges et aux meilleurs résultats. Parmi ces techniques, la plus dévelop- pée et étudiée, est la technique d’énucléation endosco- pique de la prostate à l’aide du laser Holmium (HoLEP). Le développement des lasers à usage médical ainsi que la recherche de nouvelles techniques chirurgicales mini-inva- sives ouvrent la voie à une prochaine décennie riche en innovations thérapeutiques pour la prise en charge chirur- gicale des adénomes prostatiques.

Available on ORBi :

since 27 October 2020

Statistics

Number of views

340 (8 by ULiège)

Number of downloads

6 (4 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

Bibliography

Roehrborn CG. Pathology of benign prostatic hyperplasia. Int J Impot Res 2008;20:S11-8.
Berry SJ, Coffey DS, Walsh PC, et al. The development of human benign prostatic hyperplasia with age. J Urol 1984;132:474-9.
Descazeaud A, Robert G, Delongchamps NB, et al. Association française d'urologie. Recommandations de l'Association Française d'Urologie (AFU) Disponible : https://www. urofrance.org/base-bibliographique/bilan-initial-suivi-et-Traitement-des-Troubles-mictionnels-en-rapport-Avec. Dernière consultation le 17 mars 2020.
Gravas S, Cornu JN, Drake M, et al. EAU Guidelines 2018. Management of non-neurogenic male lower urinary tract symptoms (LUTS). Disponible : https://uroweb.org/wp-content/ uploads/EAU-Guidelines-on-The-Management-of-Non-neurogenic-Male-LUTS-2018-large-Text.pdf. Dernière consultation le 17 mars 2020.
Furuya, S, Kumamoto Y, Yokoyama, E, et al. Alpha-Adrenergic activity and urethral pressure in prostatic zone in benign prostatic hypertrophy. J Urol 1982;28:836-9.
Abrams P, Schulman CC, Vaage S. Tamsulosin, a selective α1c-Adrenoceptor antagonist : A randomized, controlled trial in patients with benign prostatic obstruction (symptomatic BPH). BJU Int 1995;76:325-36.
Cornu JN, Cussenot O, Haab F, et al. A widespread population study of actual medical management of lower urinary tract symptoms related to benign prostatic hyperplasia across Europe and beyond official clinical guidelines. Eur Urol 2010;58:450-6.
Kawabe K, Yoshida M, Homma Y, Silodosin Clinical Study Group. Silodosin, a new alpha1A adrenoceptor selective antagonist for treating benign prostatic hyperplasia : results of a phase III randomized, placebo controlled, double blind study in Japanese men. BJU Int 2006;98:1019-24.
Abu-Izza, Li V, Parr G. Lifestyle and over-The-counter drugs. In: Burger A, Abraham DJ editors. Burger's medicinal chemistry and drug discovery. Autocoids, diagnostics, and drugs from new biology. 6th ed. Hoboken:John Wiley & Sons. 2013;4:421-82.
Naslund MJ, Miner M. A review of the clinical efficacy and safety of 5alpha-reductase inhibitors for the enlarged prostate. Clin Ther 2007;29:17-25.
Campbell SF. Science, art and drug discovery : A personal perspective. Clin Sci 2000;99:255-60.
European Medicines Agency. Tadalafil Lilly. Disponible : https://www.ema.europa.eu/en/medicines/human/EPAR/tadalafil-lilly#product-information-section. Dernière consultation le 17 mars 2020.
Porst H, Oelke M, Goldfischer ER, et al. Efficacy and safety of tadalafil 5 mg once daily for lower urinary tract symptoms suggestive of benign prostatic hyperplasia: subgroup analyses of pooled data from 4 multinational, randomized, placebocontrolled clinical studies. Urology 2013;82:667-73.
Food and Drug administration. Disponible : https://www.fda. gov. Dernière consultation le 17 mars 2020.
Chapple CR, Roehrborn CG. A shifted paradigm for the further understanding, evaluation, and treatment of lower urinary tract symptoms in men: focus on the bladder. Eur Urol 2006;49:651-8.
Kaplan SA. Walmsley K, Te AE. Tolterodine extended release attenuates lower urinary tract symptoms in men with benign prostatic hyperplasia. J Urol 2005;174:2273-5.
Euopean Medicines Agency. Betmiga EPAR. Disponible: https://www.ema.europa.eu/en/medicines/human/EPAR/betmiga. Dernière consultation le 17 mars 2020.
Chapple CR, Kaplan SA, Mitcheson D, et al. Randomized double-blind, active-controlled phase 3 study to assess 12-month safety and efficacy of mirabegron, a beta(3)-Adrenoceptor agonist, in overactive bladder. Eur Urol 2013;63:296-305.
Casabe A, Roehrborn CG, DaPozzo LF, et al. Efficacy and safety of the coadministration of tadalafil once daily with finasteride for 6 months in men with lower urinary tract symptoms and prostatic enlargement secondary to benign prostatic hyperplasia. J Urol 2014;191:727-33.
Föllhase C, Soler R, Gratzke C. New strategies in treating male lower urinary tract symptoms. Curr Opin Urol 2014;24:29-35.
Talab SS, Tabatabaei S. Modern open prostatectomy. In : Chughtai B, Te A, Kaplan S. editors. Treatment of benign prostatic hyperplasia: modern alternative to transurethral resection of the prostate. 1st ed. New York:Springer Science+Business Media;2015.
Millin T. The surgery of prostatic obstructions. Ir J Med Sci 1947;257:185-9.
McVary KT, Roehrborn CG, Avins AL, et al. Update on AUA guideline on the management of benign prostatic hyperplasia. J Urol 2011;185:1793-803.
Baumert H, Ballaro A, Dugardin F, et al. Laparoscopic versus open simple prostatectomy: A comparative study. J Urol 2006;175:1691-4.
Matei DV, Brescia A, Mazzoleni F, et al. Robot-Assisted simple prostatectomy (RASP): does it make sense? BJU Int 2012;110:972-9.
Nesbit RM. A history of transurethral prostatectomy. Rev Mex Urol 1975;35:249-62.
Sarkisian AM, Bernie AM, Lee R. Principles of electrocauterybased techniques. In : Chughtai B, Te A, Kaplan S. editors. Treatment of benign prostatic hyperplasia: modern alternative to transurethral resection of the prostate. 1st ed. New York:Springer Science+Business Media;2015.
Sayer J, Johnson DE, Price RE, et al. Ureteral lithotripsy with the holmium:YAG laser. J Clin Laser Med Surg 1993;11:61-5.
Gilling PJ, Cass CB, Malcolm AR, et al. Combination holmium and Nd : YAG laser ablation of the prostate : initial clinical experience. J Endourol 1995;9:151-3.
Rieken M, Bachmann A. Basic principles of laser-based techniques. Chughtai B, Te A, Kaplan S. editors. Treatment of benign prostatic hyperplasia: modern alternative to transurethral resection of the prostate. 1st ed. New York:Springer Science+Business Media;2015.